Protocol: CALBG/SWOG C80405

Contact: CPLORD@stvincent.org

Title: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab or Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

Summary: The purpose of this study is to evaluate the effects of different chemotherapy regimens for patients with metastatic adenocarcinoma of the colon or rectum. There are two common combinations of chemotherapy drugs used to treat these types of cancer. One uses 5-fluorouracil (also called 5-FU), leucovorin, and oxaliplatin, and is also called “FOLFOX.” The other combination uses 5-FU, leucovorin, and irinotecan. This combination is also called “FOLFIRI.” At the present time, the FDA has approved each of these as treatment for colon or rectal cancer. This study may determine whether cetuximab plus chemotherapy is better than bevacizumab with chemotherapy in patients who do not have K-ras mutations in their tumor tissue.

–

Protocol: P5

Contact: MRFUQUA@stvincent.org

Title: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer

Summary: The purpose of this study is to determine if rosuvastatin can prevent colon polyps and colo-rectal cancer from occurring in patients who have already had a colon cancer removed by surgery. People who have had colon cancer have a greater than average risk of developing polyps in the colon and rectum that may become colo-rectal cancer in the future. Prevention of polyps may reduce the risk of a new colo-rectal cancer.

–

Protocol: Moffitt

Contact: CPLORD@stvincent.org

Title: Total Cancer Care™: A Partnership with High Risk and/or Diagnosed Cancer Patients for Life – 14690

Summary: This study is for patients undergoing surgery at the St.Vincent Indianapolis Hospital. The patient grants permission for St.Vincent Indianapolis Hospital to have access to the tissue removed, and they donate it to the Moffitt Cancer Center for use in research. This research will pursue improving cancer treatments and patients outcomes of cancer treatments, both current and future.

Protocol: GI05-102

Contact: MRFUQUA@stvincent.org  

Title: Phase I / Randomized Phase II Study of Second Line Therapy with Irinotecan and Cetuximab with or without RAD001, an Oral m TOR Inhibitor for Patients with Metastatic Colorectal Cancer

Summary: This study is for patients with colorectal cancer that has spread beyond their colon after initial treatment with chemotherapy. The purpose of this study is to test the safety and effectiveness of RAD001 (a new chemotherapy drug to treat cancer) when given together with irinotecan and cetuximab (drugs used and approved by the Food and Drug Administration to treat colorectal cancer). The patient will receive one of three “randomized” treatments protocols.